|Metabolism||Liver (mainly CYP3A4)|
|Biological half-life||7.3–12.1 hours|
|Chemical and physical data|
|Molar mass||516.657 g/mol|
|3D model (JSmol)|
|(what is this?)|
The drug udenafil, marketed under the trade name Zydena, is within the PDE5 inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, udenafil was developed by Dong-A Pharmaceutical. With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines; in the United States, it has not been approved by the U.S. Food and Drug Administration.
- Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
- "Udenafil: Efficacy and tolerability in the management of erectile dysfunction".
- [http://www.drugs.com/international/zydena.html "Zydena", Drugs.com
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|